Generation in human plasma of misfolded, aggregation-prone electronegative low density lipoprotein

Biophysical Journal

Volumn 97, Issue 2, 2009, Pages 628-635

  Greco, Giulia ^a   Balogh, Gabor ^b   Brunelli, Roberto ^c   Costa, Graziella ^a   De Spirito, Marco ^d   Lenzi, Laura ^a   Mei, Giampiero ^e   Ursini, Fulvio ^f   Parasassi, Tiziana ^a  

^a CNR   (Italy)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; FATTY ACID; LOW DENSITY LIPOPROTEIN; LYSOPHOSPHOLIPID; PHOSPHOLIPASE A2; PLASMA PROTEIN;

ARTICLE; ENZYME ACTIVITY; HUMAN; LIPID HYDROLYSIS; LIPOLYSIS; PLASMA; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN LIPID INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; TEMPERATURE;

EID: 68849102153     PISSN: 00063495     EISSN: 15420086     Source Type: Journal    
DOI: 10.1016/j.bpj.2009.05.005     Document Type: Article

References (39)

1. Ross, R. 1999. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340:115-126.
2. Öörni, K., M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen. 2000. Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions. J. Lipid Res. 41:1703-1714.
3. Tabas, I. 1999. Nonoxidative modifications of lipoproteins in atherogenesis. Annu. Rev. Nutr. 19:123-139.
4. Chisolm, G. M., and D. Steinberg. 2000. The oxidative modification hypothesis of atherogenesis. An overview. Free Radic. Biol. Med. 28:1815-1826.
5. Steinberg, D., and J. L. Witztum. 2002. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation. 105:2107-2111.
6. Avogaro, P., G. Bittolo-Bon, and G. Cazzolato. 1988. Presence of a modified low density lipoprotein in humans. Arteriosclerosis. 8:79-87.
7. Sanchez-Quesada, J. L., C. Otal-Entraigas, M. Franco, O. Jorba, F. Gonzalez-Sastre, et al. 1999. Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patientswith heterozygous familial hypercholesterolemia. Am. J. Cardiol. 84:655-659.
8. Sanchez-Quesada, J. L., A. Perez, A. Caixas, J. Ordonez-Llanos, G. Carreras, et al. 1996. Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycemic control. Diabetologia. 39:1469-1476.
9. Moro, E., C. Zambon, S. Pianetti, G. Cazzolato, M. Pais, et al. 1998. Electronegative low density lipoprotein subform (LDL-) is increased in type 2 (non-insulin-dependent) microalbuminuric diabetic patients and is closely associated with LDL susceptibility to oxidation. Acta Diabetol. 35:161-164.
10. Benitez, S., J. L. Sanchez-Quesada, L. Lucero, R. Arcelus, V. Ribas, et al. 2002. Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. Atherosclerosis. 160:223-232.
11. Ursini, F., and A. Sevanian. 2002. Postprandial oxidative stress. Biol. Chem. 383:599-605.
12. Zhang, B., S. Miura, D. Yanagi, K. Noda, H. Nishikawa, et al. 2008. Reduction of charge-modified LDL by statin therapy in patients with CHD or CHD risk factors and elevated LDL-C levels: the SPECIAL Study. Atherosclerosis. 201:353-359.
13. Sevanian, A., G. Bittolo-Bon, G. Cazzolato, H. Hodis, J. Hwang, et al. 1997. LDL- is a lipid hydroperoxide-enriched circulating lipoprotein. J. Lipid Res. 38:419-428.
14. Parasassi, T., G. Bittolo-Bon, R. Brunelli, G. Cazzolato, E. K. Krasnowska, et al. 2001. Loss of apoB-100 secondary structure and conformation in hydroperoxide rich, electronegative LDL(-). Free Radic. Biol. Med. 31:82-89.
15. Parasassi, T., M. De Spirito, G. Mei, R. Brunelli, G. Greco, et al. 2008. Low density lipoprotein misfolding and amyloidogenesis. FASEB J. 22:2350-2356.
16. De Spirito, M., R. Brunelli, G. Mei, F. R. Bertani, G. Ciasca, et al. 2006. Low density lipoprotein aged in plasma forms clusters resembling subendothelial droplets: aggregation via surface sites. Biophys. J. 90:4239-4247.
17. Sartipy, P., G. Camejo, L. Svensson, and E. Hurt-Camejo. 2002. Phospholipase A2 modification of lipoproteins: potential effects on atherogenesis. Adv. Exp. Med. Biol. 507:3-7.
18. Hwang, J., J. Wang, P. Morazzoni, H. N. Hodis, and A. Sevanian. 2003. The phytoestrogen equol increases nitric oxide availability by inhibiting superoxide production: an antioxidant mechanism for cell-mediated LDL modification. Free Radic. Biol. Med. 34:1271-1282.
19. Hwang, J., M. H. Ing, A. Salazar, B. Lassegue, K. Griendling, et al. 2003. Pulsatile versus oscillatory shear stress regulates NADPH oxidase subunit expression: implication for native LDL oxidation. Circ. Res. 93:1225-1232.
20. Asatryan, L., R. T. Hamilton, J. M. Isas, J. Hwang, R. Kayed, et al. 2005. LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein. J. Lipid Res. 46:115-122.
21. Qu, X. W., W. P. Liu, Z. Y. Qi, Z. J. Duan, L. S. Zheng, et al. 2008. Phospholipase A2-like activity of human bocavirus VP1 unique region. Biochem. Biophys. Res. Commun. 365:158-163.
22. Tariq, M., I. Elfaki, H. A. Khan, M. Arshaduddin, S. Sobki, et al. 2006. Bromophenacyl bromide, a phospholipase A2 inhibitor attenuates chemically induced gastroduodenal ulcers in rats. World J. Gastroenterol. 12:5798-5804.
23. Dentan, C., A. D. Tselepis, M. J. Chapman, and E. Ninio. 1996. Pefabloc, 4-[2-aminoethyl]benzenesulfonyl fluoride, is a new, potent nontoxic and irreversible inhibitor of PAF-degrading acetylhydrolase. Biochim. Biophys. Acta. 1299:353-357.
24. Chen, J., L. Yang, J. M. Foulks, A. S. Weyrich, G. K. Marathe, et al. 2007. Intracellular PAF catabolism by PAF acetylhydrolase counteracts continual PAF synthesis. J. Lipid Res. 48:2365-2376.
25. Parasassi, T., M. Di Stefano, M. Loiero, G. Ravagnan, and E. Gratton. 1994. Influence of cholesterol on phospholipid bilayers phase domains as detected by Laurdan fluorescence. Biophys. J. 66:120-132.
26. Carrer, D. C., C. Vermehren, and L. A. Bagatolli. 2008. Pig skin structure and transdermal delivery of liposomes: A two photon microscopy study. J. Control. Release. 132:12-20.
27. Kudo, I., and M. Murakami. 2002. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat. 68-69:3-58.
28. Kimura-Matsumoto, M., Y. Ishikawa, K. Komiyama, T. Tsuruta, M. Murakami, et al. 2008. Expression of secretory phospholipase A2s in human atherosclerosis development. Atherosclerosis. 196:81-91.
29. Karabina, S. A., I. Brochériou, G. Le Naour, M. Agrapart, H. Durand, et al. 2006. Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function. FASEB J. 20:2547-2549.
30. Kugiyama, K., Y. Ota, S. Sugiyama, H. Kawano, H. Doi, et al. 2000. Prognostic value of plasma levels of secretory type II phospholipase A2in patients with unstable angina pectoris. Am. J. Cardiol. 86:718-722.
31. Hanasaki, K., K. Yamada, S. Yamamoto, Y. Ishimoto, A. Saiga, et al. 2002. Potent modification of low density lipoprotein by group X secretory phospholipase A2 is linked to macrophage foam cell formation. J. Biol. Chem. 277:29116-29124.
32. Rosengren, B., A. C. Jönsson-Rylander, H. Peilot, G. Camejo, and E. Hurt-Camejo. 2006. Distinctiveness of secretory phospholipase A2 group IIA and V suggesting unique roles in atherosclerosis. Biochim. Biophys. Acta. 1761:1301-1308.
33. Boekholdt, S. M., T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, et al. 2005. Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler. Thromb. Vasc. Biol. 25:839-846.
34. Ettelaie, C., P. I. Haris, N. J. James, B. Wilbourn, J. M. Adam, et al. 1997. Alterations in the structure of apolipoprotein B-100 determine the behavior of LDL towards thromboplastin. Biochim. Biophys. Acta. 1345:237-247.
35. Knott, T. J., R. J. Pease, L. M. Powell, S. C. Wallis, S. C. Rall, Jr., et al. 1986. Complete protein sequence and identification of structural domains of human apolipoprotein B. Nature. 323:734-738.
36. Hevonoja, T., M. O. Pentikäinen, M. T. Hyvönen, P. T. Kovanen, and M. Ala-Korpela. 2000. Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL. Biochim. Biophys. Acta. 1488:189-210.
37. Segrest, J. P., M. K. Jones, H. De Loof, and N. Dashti. 2001. Structure of apolipoprotein B-100 in low density lipoproteins. J. Lipid Res. 42:1346-1367.
38. Kleinman, Y., E. S. Krul, M. Burnes, W. Aronson, B. Pfleger, et al. 1988. Lipolysis of LDL with phospholipase A2 alters the expression of selected apoB-100 epitopes and the interaction of LDL with cells. J. Lipid Res. 29:729-743.
39. Brunelli, R., G. Greco, M. Barteri, E. K. Krasnowska, G. Mei, et al. 2003. One site on the apoB-100 specifically binds 17-beta-estradiol and regulates the overall structure of LDL. FASEB J. 17:2127-2129.